Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case–control study

[1]  K. Tanabe,et al.  Mechanisms of drug-eluting stent restenosis , 2020, Cardiovascular Intervention and Therapeutics.

[2]  L. Ren,et al.  MiR-132 relieves vascular endothelial inflammation and improve endothelial function in atherosclerosis rats by regulating SIRT1. , 2019, Minerva endocrinologica.

[3]  Hsiao-Ya Tsai,et al.  Roles of the hypoximir microRNA‐424/322 in acute hypoxia and hypoxia‐induced pulmonary vascular leakage , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  I. Mills,et al.  Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer , 2019, Scientific Reports.

[5]  R. Marfella,et al.  Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study , 2019, Cardiovascular Diabetology.

[6]  C. Indolfi,et al.  Non-coding RNAs in vascular remodeling and restenosis. , 2019, Vascular pharmacology.

[7]  C. Gross,et al.  MicroRNA‐induced silencing in epilepsy: Opportunities and challenges for clinical application , 2018, Developmental dynamics : an official publication of the American Association of Anatomists.

[8]  M. Hirata,et al.  Modulation of miR-26a-5p and miR-15b-5p Exosomal Expression Associated with Clopidogrel-Induced Hepatotoxicity in HepG2 Cells , 2017, Front. Pharmacol..

[9]  A. Colombo,et al.  Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory? , 2017, Journal of the American College of Cardiology.

[10]  Donncha F. O’Brien,et al.  Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus , 2017, Scientific Reports.

[11]  S. Biffo,et al.  Role of microRNAs in translation regulation and cancer , 2017, World journal of biological chemistry.

[12]  Wei Huang,et al.  MicroRNA regulatory pathway analysis identifies miR-142-5p as a negative regulator of TGF-β pathway via targeting SMAD3 , 2016, Oncotarget.

[13]  Min Gyu Lee,et al.  A feedback loop comprising PRMT7 and miR-24-2 interplays with Oct4, Nanog, Klf4 and c-Myc to regulate stemness , 2016, Nucleic acids research.

[14]  Patrick M. Looser,et al.  In-Stent Restenosis: Pathophysiology and Treatment , 2016, Current Treatment Options in Cardiovascular Medicine.

[15]  Guoqing Hu,et al.  MicroRNA-15b/16 Attenuates Vascular Neointima Formation by Promoting the Contractile Phenotype of Vascular Smooth Muscle Through Targeting YAP , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[16]  G. Condorelli,et al.  Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. , 2015, Circulation research.

[17]  Lin Wang,et al.  Upregulation of miR-142-5p in atherosclerotic plaques and regulation of oxidized low-density lipoprotein-induced apoptosis in macrophages , 2015, Molecular medicine reports.

[18]  D. Franco,et al.  Identification of regulatory elements directing miR-23a-miR-27a-miR-24-2 transcriptional regulation in response to muscle hypertrophic stimuli. , 2014, Biochimica et biophysica acta.

[19]  F. Pasquier,et al.  A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles , 2014, Alzheimer's Research & Therapy.

[20]  Fernando Alfonso,et al.  Current treatment of in-stent restenosis. , 2014, Journal of the American College of Cardiology.

[21]  Y. Ahn,et al.  The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. , 2013, Atherosclerosis.

[22]  T. Capiod,et al.  miR-424/322 regulates vascular smooth muscle cell phenotype and neointimal formation in the rat. , 2013, Cardiovascular research.

[23]  A. Chakravarti,et al.  Identification of Sensitive Serum microRNA Biomarkers for Radiation Biodosimetry , 2013, PloS one.

[24]  D. Gómez-Garre,et al.  Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. , 2012, Pharmacological research.

[25]  Soo-Jin Kang,et al.  In-stent neoatherosclerosis: a final common pathway of late stent failure. , 2012, Journal of the American College of Cardiology.

[26]  G. Paolisso,et al.  Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. , 2012, The Journal of clinical endocrinology and metabolism.

[27]  Inyoul Lee,et al.  Extracellular microRNA: a new source of biomarkers. , 2011, Mutation research.

[28]  G. Reid,et al.  Circulating microRNAs: Association with disease and potential use as biomarkers. , 2011, Critical reviews in oncology/hematology.

[29]  L. Penalva,et al.  MicroRNA-16 and MicroRNA-424 Regulate Cell-Autonomous Angiogenic Functions in Endothelial Cells via Targeting Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Wenhuo Hu,et al.  The role of microRNAs in hematopoietic stem cell and leukemic stem cell function , 2011, Therapeutic advances in hematology.

[31]  G. Paolisso,et al.  Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. , 2011, The Journal of clinical endocrinology and metabolism.

[32]  G. Niccoli,et al.  The evolving role of inflammatory biomarkers in risk assessment after stent implantation. , 2010, Journal of the American College of Cardiology.

[33]  Taous Khan,et al.  MicroRNAs: synthesis, mechanism, function, and recent clinical trials. , 2010, Biochimica et biophysica acta.

[34]  A. Šimundić.  Measures of Diagnostic Accuracy: Basic Definitions , 2009, EJIFCC.

[35]  G. Paolisso,et al.  The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes , 2007, Cardiovascular diabetology.

[36]  A. Zwinderman,et al.  Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions , 2005, Circulation.

[37]  S. Grundy,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association , 2002, Circulation.

[38]  Shile Huang,et al.  Mechanisms of resistance to rapamycins. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  T. Meinertz,et al.  Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis , 2000, The Lancet.

[40]  V. Fuster,et al.  Management of restenosis after coronary intervention. , 1996, American heart journal.

[41]  J. Natarajan,et al.  Prediction of microRNAs involved in immune system diseases through network based features , 2017, Journal of Biomedical Informatics.

[42]  A. Zwinderman,et al.  Tumor necrosis factor-alpha plays an important role in restenosis development. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.